
FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxOT3N6YkdfVTd6enpzOHB5eVVSM2VkdGVqV1hkRnNkVFM3SEV6dDRmNXMtRVp1Yng3Vi0wc01MbC0yWXNIMnhZUXNlakRZZ0FBZll6WXVmLU5tc2JiVmlJakFLNk5iYmUtTmlpRy1FTS13Y21pRWZEQzJRUVhPdEV6NW1qRjE0b0ZCYTROcGNfYmE3Zm53d1pfT3hQZnI5LTJJVGVzdTF2TkN4SFU?oc=5" target="_blank">FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301</a>&nbsp;&nbsp;<font color="#6f6f6f">The American Journal of Managed Care</font>
